Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vaccine adjuvant: it makes the difference.

Karla M Lima1, Sandra Aparecida dos Santos, José M Rodrigues

  • 1Center for Tuberculosis Research, School of Medicine of Ribeirão Preto, Instituto do Milênio Rede-TB, University of São Paulo, Avenue Bandeirantes 3900, Ribeirão Preto, São Paulo 14049-900, Brazil.

Vaccine
|June 15, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Dual Immunoregulatory Role of CREB3L1 Underlying Latent and Severe Tuberculosis Clinical Manifestation.

Immunology·2025
Same author

Immunomodulatory activity of hyaluronidase is associated with metabolic adaptations during acute inflammation.

Inflammation research : official journal of the European Histamine Research Society ... [et al.]·2019
Same author

Therapeutic effect of DNA vaccine encoding the 60-kDa-heat shock protein from Paracoccidoides brasiliensis on experimental paracoccidioidomycosis in mice.

Vaccine·2019
Same author

Recombinant BCG Expressing LTAK63 Adjuvant induces Superior Protection against Mycobacterium tuberculosis.

Scientific reports·2017
Same author

New strategy for testing efficacy of immunotherapeutic compounds for diabetes in vitro.

BMC biotechnology·2016
Same author

Investigation of local anesthetic and antimycobacterial activity of Ottonia martiana Miq. (Piperaceae).

Anais da Academia Brasileira de Ciencias·2015

Adjuvants are crucial for vaccine effectiveness when using non-living components like proteins or DNA. This study highlights how formulation, specifically adjuvant use, significantly impacts immune response and protection against tuberculosis.

Area of Science:

  • Immunology
  • Vaccinology
  • Microbiology

Background:

  • Protein and DNA vaccines offer enhanced safety over live or attenuated vaccines.
  • Adjuvants are often necessary to boost the immunogenicity of subunit vaccines.
  • Tuberculosis vaccines serve as a model to investigate adjuvant roles.

Purpose of the Study:

  • To demonstrate the critical importance of adjuvants in vaccine formulations.
  • To explore how vaccine formulation influences immune response and protective efficacy.

Main Methods:

  • Utilized a vaccine formulation based on the 65 kDa heat shock protein (hsp65) from Mycobacterium tuberculosis.
  • Administered the same antigen with different formulations to mice.
  • Assessed the protective efficacy against Mycobacterium tuberculosis challenge.

Related Experiment Videos

Main Results:

  • The same antigen (hsp65) elicited distinct immune response patterns based on formulation.
  • Vaccine formulation, particularly the presence and type of adjuvant, determined protection against M. tuberculosis challenge in mice.
  • The adjuvant significantly influenced the outcome of vaccination.

Conclusions:

  • Adjuvants play a fundamental role in the efficacy of subunit vaccines, contrary to their name suggesting only an auxiliary function.
  • Vaccine formulation is a key determinant of protective immunity.
  • Optimizing adjuvant use is essential for developing effective non-living vaccines.